Merus N.V. (MRUS)

Market Cap	4.89B
Revenue (ttm)	56.23M
Net Income (ttm)	-385.52M
Shares Out	75.63M
EPS (ttm)	-5.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,580
Open	63.89
Previous Close	63.77
Day's Range	63.89 - 63.89
52-Week Range	33.19 - 67.59
Beta	1.09
Analysts	Strong Buy
Price Target	91.00 (+40.73%)
Earnings Date	Aug 5, 2025

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumor...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 19, 2016
• Employees: 321
• Stock Exchange: NASDAQ
• Ticker Symbol: MRUS
• Website: https://www.merus.nl

Financial Performance

In 2024, Merus's revenue was $36.13 million, a decrease of -17.78% compared to the previous year's $43.95 million. Losses were -$215.33 million, 39.0% more than in 2023.

Analyst Forecast

According to 12 analysts, the average rating for MRUS stock is "Strong Buy." The 12-month stock price target is $91.0, which is an increase of 40.73% from the latest price.

Price Target

$91.0

(40.73% upside)

Analyst Consensus: Strong Buy